Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Critical Rheumatic Mitral Stenosis Unmasked During Pregnancy Complicated by Preeclampsia With Severe Features and Managed With Urgent Balloon Mitral Valvuloplasty

Gorsi U, Kim N, Sukhija R, Kumar J, Nabavizadeh P. Critical Rheumatic Mitral Stenosis Unmasked During Pregnancy Complicated by Preeclampsia With Severe Features and Managed[...]

Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis

Gu Y, Gebremariam T, Ibrahim BA, Harb K, Chan A, Ibrahim AS. Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis. J Fungi (Basel).[...]

Initial Results Do Not Support That Fully Virtual Pulmonary Rehabilitation Widens Reach to Underserved Patients With COPD

Moy ML, Casaburi R, Nici L. Initial Results Do Not Support That Fully Virtual Pulmonary Rehabilitation Widens Reach to Underserved Patients With COPD. Chronic Obstr[...]